August 25th, 2020--Cambridge

Isomerase Therapeutics Ltd (Cambridge, UK), is delighted to announce that it has fully moved operations from the Science Village into the newly refurbished Newnham Building at Chesterford Research Park.

CEO of Isomerase, Dr Matthew Gregory commented “Not only is this new space twice the size of our previous facilities, but we have also been closely involved in the design, ensuring it is ideally suited to our needs as a leading-edge synthetic biology company. We now have dedicated space to accommodate an increase in our fermentation capacity. We have also increased air handling to improve staff comfort and include additional walk-in fume cupboards and ventilated enclosures. We have enough space to support the next phase in the company’s growth. This new lease underpins our long-term business plan for the company to expand our capabilities and support clients across a wide range of biotechnology applications.”

Steven Moss, the CTO of Isomerase continued “The new building offers a high-quality work environment for conducting excellent science. The laboratory is specifically designed to support the material and process flows around our work cycle within synthetic biology, chemistry and bioprocess development.”

About Isomerase
Our team is uniquely placed to assist partners with all aspects of microbial product and process discovery and development, including leading-edge synthetic biology, advanced strain improvement of microorganisms, genome sequence analysis, protein and peptide expression and isolation, fermentation and process development, DSP, compound isolation, analytical development and synthetic chemistry. In addition, Isomerase manages other aspects necessary for a commercially successful programme on behalf of partners, such as compound management and shipping and scaled manufacture.

We offer these capabilities underpinned by a portfolio of technology IP, and the combined experience of a core technical and leadership team with a substantive track record of successful product discovery and development collaborations with pharma and biotech companies.

We have supported numerous companies with a wide variety of microbial product and small molecule fermentation and synthetic chemistry projects, helping advance early stage concepts into valuable development programmes, and then continuing to support their progress to market with process improvement and scaled manufacture.

For more information please contact Isomerase via our contact page.

Breadcrumbs